BMI shouldn’t be the only way to assess who can access weight-loss drugs
Antonio_Diaz/Getty ImagesAround one in three Australian adults (32%) has a body-mass index (BMI) of 30 or above. A further 34% has a BMI of 25 or above.
Australia’s regulator has approved Wegovy, the weight-loss version of Ozempic (semaglutide) and Mounjaro (tirzepatide) for weight management, alongside a reduced-calorie diet and exercise.
To...
	




